WA-SPIE
17.12.2020 17:07:15 CET | Business Wire | Press release
SPIE Photonics West , which normally convenes in San Francisco, will be held as an interactive, virtual conference 6-11 March 2021. North America’s largest optics and photonics technology event – with its popular BiOS, LASE, and OPTO conferences – held by SPIE, the international society for optics and photonics , also includes two digital exhibitions and the industry-focused Quantum West. Registration for SPIE Photonics West will open 5 January.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201217005110/en/
In addition to SPIE Photonics West, the following SPIE 2021 conferences will also be held via the organization’s digital-forum platform: SPIE Advanced Lithography ; SPIE Medical Imaging ; SPIE AR/VR/MR ; and SPIE Smart Structures + Nondestructive Evaluation .
“The SPIE Digital Forum platform was developed to help people share results and make connections during the pandemic, and we’ve continued to fine-tune our virtual platform and digital offerings throughout this year,” says SPIE CEO Kent Rochford. “We’ll be implementing the latest improvements during Photonics West and are excited to release them to our attendees, presenters, and exhibitors. These forums, as always, ensure the professional discussion, innovation sharing, and networking opportunities that the SPIE community values and relies on to advance its research, product development, and engineering collaborations.”
"It's been a challenging year for our entire community, and I know that I am not alone in my desire to meet in person to exchange ideas, research, technological advances, and new products," says 2020 SPIE President John Greivenkamp. "We are hopeful of being able to gather in person later in 2021. In the meantime, I invite you to join us online at one or more of these dynamic conferences and look forward to seeing you there."
Each year, SPIE Photonics West showcases the latest in applications, technologies, and discoveries in optics and photonics, with three major conference tracks: BiOS, highlighting new research in biophotonics, biomedical optics, and applications of medical imaging; LASE, with its focus on the laser industry and applications; and OPTO, showcasing optoelectronics, photonic materials, and related devices. In addition, the symposium is introducing a new conference, highlighting photonics research and technologies addressing COVID-19 . Photonics West will also feature a Digital Marketplace with product demos showcasing the latest in optics and photonics technologies and opportunities to connect with the industry’s leading suppliers and companies.
The SPIE Digital Forums will offer a convenient, high-quality, and timely way for researchers, engineers, and government and industry leaders in the photonics community to share emerging research, new results, and technological advances with their peers. The SPIE online format makes presentations and discussion accessible during the Forum in whatever time zone is convenient for the participant and in any order. In addition, the Digital Forums will include networking opportunities, live plenary sessions, and special events. All conference presentations and manuscripts will be accessible after the conference via the SPIE Digital Library . Registration and pricing information is available on each event webpage.
About SPIE
SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5.8 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005110/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom